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Abstract
Background—Estrogen is the leading etiologic factor for endometrial cancer. Estrogen-induced
proliferation of endometrial epithelial cells normally requires paracrine growth factors produced
by stromal cells. Epidemiologic evidence indicates that dietary soy prevents endometrial cancer,
and implicates the phytoestrogen genistein in this effect. However, results from previous studies
are conflicting regarding the effects of genistein on hormone responsive cancers.
Methods—The effects of estrogen and genistein on proliferation of Ishikawa (IK) endometrial
adenocarcinoma cells were examined in co-cultures of IK cells with endometrial stromal cells,
recapitulating the heterotypic cell-to-cell interactions observed in vivo. The roles of estrogen
receptor (ER)α and ERβ were evaluated using ERα and ERβ specific agonists. ER activation and
cell proliferation in the IK epithelial cells were determined by alkaline phosphatase assay and
Coulter counter enumeration, respectively.
Results—Both estrogen and genistein increased estrogen receptor-induced gene activity in IK
cells over a range of concentrations. Estrogen alone but not genistein increased IK proliferation in
co-cultures. When primed by estrogen treatment increasing concentrations of genistein produced a
biphasic effect on IK proliferation: nM concentrations inhibited estrogen-induced proliferation
while µM concentrations increased proliferation. Studies with an ERβ-specific agonist produced
similar results. Genistein did not influence the effects of estrogen on IK proliferation in
monoculture.
Conclusions—Our study indicates that nutritionally relevant concentrations (nM) of genistein
inhibit the proliferative effects of estrogen on endometrial adenocarcinoma cells presumably
through activation of stromal cell ERβ. We believe that sub-micromolar concentrations of
genistein may represent a novel adjuvant for endometrial cancer treatment and prevention.
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INTRODUCTION
Endometrial cancer is invasive gynecological cancer with the highest incidence in
economically advantaged countries (Jemal et al., 2010; American Cancer Society, 2010).
Elevated estrogen (17β-estradiol) levels, whether from natural, environmental, or therapeutic
sources, when not opposed by sufficient progesterone, increases a woman’s risk of
developing type I (endometrioid) endometrial cancer, the most prevalent form of this disease
(Gambacciani et al., 2003; Weiderpass et al., 1999). The relative risk for women who have
ever used estrogen replacement therapy (ERT) ranges from 1.4 to 10 when compared to
those who have not (Gambacciani et al., 2003; Neves-E-Castro, 2008; Weiderpass et al.,
1999). Additional epidemiological factors have been shown to influence the risk of
developing endometrial cancer; however, all are directly or indirectly associated with
estrogen exposures (Jemal et al., 2010, Amant et al., 2005; Lambe et al., 1999; Parazzini et
al., 1994; Kaaks, 2004; Wolin et al., 2010). The addition of progesterone, a hormone that
antagonizes effects of estrogen, ameliorates continuous estrogen-stimulated cell proliferation
in the endometrium reducing the risk of endometrial cancer (Hulka et al., 1982). These data
further emphasize the role of unopposed estrogen on endometrial cancer development.
However, the mechanism underlying the malignant transformation of endometrial cells
resulting from prolonged estrogen exposure is not thoroughly understood.
Phytoestrogens are plant-derived compounds that resemble the human reproductive hormone
estrogen (E2) chemically and have estrogenic or anti-estrogenic activity. Soybeans and soy
product are rich in several phytoestrogens and the isoflavone genistein is the major
phytoestrogen component in these products. In recent years phytoestrogens like genistein
have become a popular dietary supplement used to lessen symptoms of menopause.
Concerns have been raised regarding the potential of these products to adversely affect the
function of hormone-sensitive tissues and potentiate the development and growth of
hormone-sensitive cancers, such as breast, ovarian, and endometrial. Conversely,
epidemiologic studies have shown that populations consuming diets rich in soy products
have lower incidence rates of these hormone-related cancers (Rozman et al., 2006).
Although the anti-cancer mechanisms of soy products are unknown, genistein has been
shown to exert diverse biological effects. At low concentrations, genistein is reported to
interact with the estrogen receptor (ER), while at high concentrations genistein acts as a
tyrosine kinase inhibitor (Peterson, 1995; Wang et al., 1996). Although genistein is able to
bind both subtypes of the ER, it has a higher binding affinity for the ER subtype β (ERβ)
(Peterson, 1995). ERβ activation is thought to antagonize ERα activation through various
mechanisms (Saji et al., 2005), and therefore treatment of estrogen-responsive cancers with
genistein might antagonize estrogen-induced responses like cell proliferation. However,
conflicting evidence indicate that genistein may possess both estrogen-antagonizing and
estrogen-potentiating actions (Diel et al., 2004; Diel et al., 2006; Kijkuokool et al., 2006;
Mylonas et al., 2003). These controversies extend to the association of phytoestrogen
treatments and endometrial cancer. To date there is no consensus on doses of phytoestrogens
that may cause adverse effects or the doses that yield optimal benefit to risk ratios,
particularly for the purified isoflavone genistein.
Past studies of the effects of estrogen and/or genistein using endometrial cells have been
restricted by the lack of an adequate model of hormone responsive endometrium in vitro. To
address the role of genistein in an in vitro model system that more accurately represents the
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endometrium in vivo, we have developed a novel co-culture system. This model
reconstitutes the humoral heterotypic cell-to-cell interactions mediated by soluble factors
that regulate hormonal influences on cell proliferation like those found in the human
endometrium in vivo (Arnold et al., 2001; Arnold et al., 2002; Barbier et al., 2005; Barbier et
al., 2008). Using this system, previous studies showed that estrogen-induced epithelial cell
proliferation and responsiveness to progestins was dependant on the presence of endometrial
stromal cells in co-culture with the epithelial cells (Arnold et al., 2001; Arnold et al., 2002;
Barbier et al., 2005; Barbier et al., 2008). A similar mechanism involving stromal-epithelial
interaction has been demonstrated to be essential for estrogen-induced proliferation in the
mouse endometrium (Cooke et al., 1988; Cooke et al., 1997; Cunha et al., 2004). In the
study reported here we investigated the effects of nutritionally relevant concentrations of the
phytoestrogen genistein on estrogen-induced responses using an Ishikawa (IK) endometrial
adenocarcinoma co-culture system. Endpoints investigated included cell proliferation and
the alkaline phosphatase (ALPP) assay, a commonly used marker of ER activation and ER-
dependent differentiation. We evaluated the role of stromal cells in these responses by
comparison of monocultures of IK cells to co-cultures of IK cells and endometrial stromal
cells. We also explored the roles of ERα and ERβ using receptor specific agonists to
distinguish the mechanisms of action of genistein.
MATERIALS AND METHODS
Reagents and Cell Culture
Genistein and 17β-estradiol were obtained from Sigma (St. Louis, MO). The ERα agonist
4,4', 4"-(4-Propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) and the ERβ agonist
diarylpropio-nitrile (DPN) were obtained from TOCRIS (Ellisville, MO). The immortalized
noncancerous human endometrial stromal cell line SHT290 (SHT) was developed in our
laboratory (Barbier et al., 2005); the human Ishikawa (IK) endometrial adenocarcinoma
epithelial cell line (Nishida et al., 1985) was obtained from Dr. Bruce Lessey (Greenville
Hospital System University Medical Center, Greenville South Carolina). For 24 hr prior to
treatment cell lines were maintained in steroid-free “JAC4” medium consisting of a 1:1
mixture of Ham F12 (GIBCO, Invitrogen Corp, Carlsbad, CA) and M199 basic medium
(Sigma) supplemented with 4% charcoal-stripped fetal bovine serum (Hyclone, Logan UT),
0.25% ITS+ (insulin-transferin-selenium plus lipoic acid, BD Biosciences, Becton
Dickinson, Franklin Lakes, NJ), 0.1 mM phosphorylethanolamine (Sigma) and 2 mM L-
glutamine (GIBCO) and antibiotic/antimycotic solution (GIBCO) diluted to yield 100 units/
mL penicillin G sodium, 100 µg/mL streptomycin sulfate and 250 ng/mL amphotericin B.
All cultures described in this report were maintained at 37°C in a humidified atmosphere of
5% CO2.
Assessment of Cell Proliferation
Stromal cells grown in JAC4 medium were seeded in multi-well culture plates (Corning)
and Ishikawa adenocarcinoma cells grown in JAC4 were seeded onto cell culture transwell
inserts with 0.4 µm porosity (Falcon) that were placed into appropriately sized multi-well
culture plates. The next day, inserts containing IK cells were placed into the multi-well plate
containing SHT cells to create an in vitro model of early type I endometrial cancer. Co-
cultures were established with an epithelial to stromal cell ratio of 1:5. Inserts were seated in
culture wells such that the IK cells were suspended above the adherent stromal cells,
allowing for soluble interactions without direct contact between the two cell types. To assess
proliferation at the end of the experiment, IK cells were detached from the inserts using a
1:1 mixture of versene (GIBCO) and trypsin-EDTA, thoroughly mixed to obtain single cell
suspensions, and enumerated using a Coulter Counter (Beckman Coulter, Inc., Fullerton,
CA).
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For assays of the effects of single hormones, co-cultures were first equilibrated in steroid-
free JAC4 for 24 hr. Thereafter, the co-cultures were treated by addition of 17β-estradiol
(0.01 to 1000 nM in log10 increments), genistein (10, 50, 100, 500 and 1000 nM), the ERα
specific agonist PPT (1, 10, 100 and 1000 nM) or the ERβ specific agonist DPN (1, 10, 100
and 1000 nM) into separate co-cultures. Subsequently, the co-cultures were maintained in
JAC4 with the same hormone-concentration for 6 days, with replacement of the hormone-
containing media every 48 hr to ensure proper dosing. At the end of this treatment period,
the media was removed, the cells washed twice in ice cold Hanks’ Buffered Saline Solution
(HBSS), and the epithelial cells were trypsinized and counted. Control cultures were treated
with only the vehicle used to dissolve hormones.
To assess the effect of genistein on estrogen-driven proliferation, co-cultures acclimated to
the serum-free JAC4 media for 24 hr were treated with JAC4 media supplemented with
physiologic (10 nM) estrogen for 48 hr, after which the medium was changed to JAC4
supplemented with a combination of 10 nM estrogen and increasing concentrations of
genistein. The media was changed after 48 hr and the treatment continued for an additional
48 hr, resulting in a total of 6 days of treatment as noted previously. Similar studies were
conducted to assess the effects of increasing concentrations of the ERβ agonist DPN on
estrogen induced IK proliferation in the co-culture model. Following treatments, IK
epithelial cells were washed, trypsinized and counted as described above. Control cultures
were treated with only 10 nM estrogen for the duration of the experiment (6 days).
Alkaline Phosphatase Assay to Determine Estrogen Receptor Activation
Estrogen receptor activation was determined indirectly by assessing estrogen-induced, ER-
mediated gene activation using an alkaline phosphatase (ALPP)-based bioassay following
the protocol developed by Littlefield et al. (1990). Briefly, on the day of the experiment, IK
cells were seeded at a density of 7×103 cells per well of a 96-well flat bottom micro-titer
plate (Corning Inc - Costar, Acton MA) in normal growth medium and allowed to adhere for
24 hr. Additionally, SHT stromal cells were seeded onto transwell inserts at a density of
3.5×104 and allowed to adhere for 24 hr, after which IK cells and SHT cells were brought
together to create co-cultures. IK/SHT co-cultures then were treated with vehicle control,
estrogen or genistein. After addition of test compounds diluted in growth medium (200 µL/
well), cells were incubated for 72 hr at 37°C in a humidified atmosphere of 5% CO2. At the
conclusion of the experiment, the stromal cells on the inserts were removed from the co-
cultures and the medium was removed from the micro-titer plates by inverting and shaking.
The adherent IK cells were subsequently washed twice with 0.15 M NaCl containing 10 mM
sodium phosphate (1× PBS), pH 7.4 (GIBCO). Following the last wash, the plates were
blotted over clean paper towels, 100 µL of methanol (Mallinckrodt Chemicals) was then
added to each well, and the plates were incubated at −70°C for 20 min. The plates were
removed from −70°C and maintained at room temperature for 5 min. The methanol was
removed and 100 µL of ALPP substrate, p-nitrophenyl phosphate (pNPP, Sigma), plus 0.24
mM MgCl2, and 1 mM diethanolamine (pH 9.8) was added to each well. Plates were
protected from light and incubated at room temperature for approximately 3 hr. Following
incubation, the metabolism of pNPP by the ER-responsive gene product ALPP in IK
epithelial cells was assessed by the colorimetric change of the fluid present in each well of
the culture dishes as determined by absorption at 405 nm wavelength in a spectrophotometer
(680 Microplate Reader, BioRad).
Statistical Analysis
Each experimental value was derived from a total of six co-cultures per treatment unless
otherwise stated and the mean values and standard deviations of the mean were calculated.
Each experiment was repeated at least twice. Data were analyzed using a homoscedastic
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Student T-test. In the Figures data are presented as the mean ± SD. Values that met the
criteria of statistical significance at P < 0.05 were denoted with an “*” or “#” and those that
were significant at P < 0.01 were denoted with a “**” in the Figures.
RESULTS
Proliferation and Estrogen Receptor Activation by Estrogen or Genistein
Previous studies have shown that the basal rate of proliferation of endometrial epithelial
cells is higher in monoculture than in co-culture (Arnold et al., 2001) indicative of the
inhibitory effects of stromal cells on IK cell proliferation. This inhibitory effect of stromal
cells was confirmed by the finding that IK cell proliferation also was decreased when they
were cultured with medium conditioned by the growth of stromal cell monocultures (Arnold
et al., 2002). Additionally, we have shown that the increased IK cell proliferation induced by
estrogen in our co-culture model is dependent on the presence of stromal cells, and that this
increase in proliferation is higher if stromal factors are permitted to accumulate during the
experiment by changing the medium less frequently (Barbier et al., 2005).
To investigate the role of estrogen and genistein on endometrial cell proliferation, we used
IK (epithelial) cells in co-cultures with SHT endometrial stromal cells. Expression of both
estrogen receptors ERα and ERβ by the IK cell line was supported by Western blot analysis
of total cell lysates (data not shown). Expression of receptors ERα and ERβ by SHT290
endometrial stromal cells has been reported previously (Barbier et al., 2005). The functional
integrity of estrogen receptors in IK cells was confirmed by assessing the effect of estrogen
on ER-regulated induction of ALPP activity (Littlefield et al., 1990). In these studies ER-
mediated induction of ALPP activity was assessed in IK cells in response to a range of
concentrations of estrogen (0.01 to 1000 nM) or genistein (10 to 1000 nM); control cultures
were treated only with vehicle. Both estrogen and genistein treatments produced dose-
dependent increases in ER activity up to the point of saturation of activity (Figure 1A and
1B, respectively). Full activation of ER was achieved at 1 nM estrogen while it required 500
nM of genistein to achieve saturation.
Having shown that IK cells in co-culture were responsive to the estrogen- and genistein-
induced ER activation, the effects of graded concentrations of estrogen or genistein on IK
cell proliferation were evaluated. Figure 2A demonstrates that estrogen increased IK cell
proliferation in a concentration-dependent manner over the range of concentrations shown to
mediate ER activation as determined by induction of ALPP activity (Figure 1A). Again, the
maximum effect was observed at 1 nM estrogen. In contrast, Figure 2B shows that genistein
did not induce IK proliferation in endometrial co-cultures over a range of concentrations (1,
10 and 100 nM), despite the fact that these concentrations were shown to induce ER
activation as assessed by increasing alkaline phosphatase activity in endometrial co-cultures
(Figure 1B).
Proliferation and Estrogen-Induced Enzyme Activation by ERα or ERβ Specific Agonists
Previous research indicated that estrogen and genistein have different affinities for the two
estrogen receptor subtypes (Peterson, 1995). To investigate the basis for the observed
differences between estrogen and genistein treatment on ER activity (Figure 1) and on cell
proliferation (Figure 2) of IK cells in the co-culture model, we evaluated whether
differences in the affinities for ERα or ERβ reported for estrogen and genistein might be
responsible. We performed studies similar to those described above (Figures 1 and 2) but
substituted PPT and DPN, which are selective agonists for ERα and ERβ, respectively, for
estrogen and genistein.
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Figure 3A shows that the ERα agonist PPT activated ER activity in a dose dependent
manner, much like the response shown with increasing estrogen concentrations. Analogous
to genistein, the ERβ agonist DPN increased ER activity in a concentration dependent
manner (Figure 3B). Although treatment of endometrial co-cultures with 10 nM PPT (Figure
4, column 3) increased IK cell proliferation, it did not reach the level produced by 10 nM
estrogen (Figure 4, column 2). In comparison to the estrogen treatment curve shown in
Figure 2, 10 nM genistein produced a level of IK proliferation similar to the level produced
by 0.1 nM estrogen. Like genistein, treatment of IK co-cultures with 10 nM DPN did not
increase IK proliferation above the control level (Figure 4, column 4).
Effect of Genistein on Estrogen-Induced IK Growth in Co-culture
Although genistein alone had no proliferative effect on IK cells in our co-culture system
(Figure 2B), previous research indicated that genistein could antagonize proliferation
induced by estrogen in vivo (Diel et al., 2006). Therefore, IK cells in monoculture or co-
culture were primed with estrogen (10 nM) for 48 hr, followed by co-treatment with
estrogen and increasing concentrations of genistein. Treatment of IK monocultures with 10
nM estrogen produced an increase in IK cell proliferation in monoculture that was
unaffected by the addition of 10 or 1000 nM genistein (Figure 5A). In contrast, the
combination of estrogen with genistein in the IK co-culture system had a complex effect on
epithelial cell proliferation. When compared to treatment of IK co-cultures with estrogen
alone (Figure 5B, column 2), increasing concentrations of genistein in the range that is
nutritionally relevant (1, 10 and 100 nM) (Rozman et al., 2006; Cassidy, 2006) decreased
estrogen-induced proliferation of IK epithelial cells by approximately 15% increments for
each log increase of the dose (Figure 5B, columns 3, 4, and 5, respectively). A maximum
inhibition of the estrogen-stimulated proliferative response was achieved at 100 nM
genistein (a 45% decrease in estrogen induced proliferation). However, at 1000 nM, a super-
physiologic concentration when considered in relation to modern Western diets, genistein no
longer inhibited estrogen-induced proliferation but potentiated cell proliferation above the
level induced by estrogen alone (Figure 5B, column 6).
Genistein has been reported to have a higher affinity for ERβ than for ERα (Peterson, 1995).
In view of this we hypothesized that the concentration-dependent biphasic epithelial
proliferative response produced by increasing concentrations of genistein in estrogen-
induced co-cultures (Figure 5) might be attributed to the differences in binding of genistein
to the two estrogen receptors. We hypothesized further that at low doses, genistein
principally affects ERβ-mediated processes whereas at super-physiologic doses genistein
might mediate its effects through ERα. To test this hypothesis, we investigated the
relationship between the concentration of the ERβ-specific agonist DPN and its effect on
estrogen-induced proliferation (Figure 6). When compared to estrogen stimulated controls
(10 nM, Figure 6, column 1), increasing concentrations of DPN decreased estrogen-induced
proliferation by 33% at 10 nM DPN (Figure 6, column 4); this level of inhibition of
proliferation is comparable to that produced by 10 nM genistein (Figure 5B, column 3). At
the highest concentration studied (100 nM) there was less inhibition (19%) of IK cell
proliferation by DPN (Figure 6, column 5). This relative increase of proliferation by 100 nM
DPN compared to that at 10 nM DPN is similar to the increase of proliferation observed at
the highest concentration of genistein (1000 nM) in the estrogen-stimulated model (Figure
5B, column 6).
DISCUSSION
Numerous studies document that estrogen is the principal etiologic factor for the
development of type I endometrial cancer. Soy and soy products are thought to prevent
carcinogenesis based on epidemiologic evidence indicating that diets rich in soy are
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protective against hormone-associated cancers such as that of the breast, prostate, colon and
endometrium (Rozman et al., 2006). Genistein is the most abundant phytoestrogen in soy.
Numerous studies in animals have explored the effects of genistein and soy isolates on
breast and prostate cancer in recent years, but the results are conflicting (Kijkuokool et al.,
2006; Hillman et al., 2004; Rahal and Simmen, 2010; Harper et al., 2009; Singh-Gupta et
al., 2010; Martinez-Montemayer et al., 2010; Raffoul et al., 2007). Few studies, however,
have considered effects of these nutritional components on the induction of cancer of the
endometrium. Additionally, the mechanisms by which genistein and soy isolates influence
cancer development remain obscure, particularly for the endometrium. A better
understanding of the effects of genistein and soy products on the endometrium and on the
development of endometrial cancer is needed to address its relevance in menopause and for
its potential utility as a therapeutic or preventative agent for this form of cancer.
Studies in our laboratory have demonstrated that heterotypic cell-to-cell interactions in co-
cultures of human endometrial stromal and epithelial cells are necessary for appropriate
hormonal and metabolic responses of endometrial epithelial cells in vitro that resemble those
found in vivo (Arnold et al., 2001; Arnold et al., 2002; Barbier et al., 2005; Barbier et al.,
2008). Therefore, reconstituting a microenvironment in vitro that permits interactions
between endometrial stromal cells and endometrial epithelial cells facilitates more accurate
investigations into the mechanisms of action of estrogen and/or soy phytoestrogens in
endometrium. The aim of this study was to determine whether the presence of the stromal
cells influenced the effect of the phytoestrogen genistein on endometrial epithelial cell
proliferation when it was used alone or in combination with estrogen stimulation.
Recently, Diel et al. reported anti-estrogenic effects of “low dose” genistein in intact rats
and ovariectomized rats co-treated with physiologic doses of estrogen (Diel et al., 2004; Diel
et al., 2006), using dosing levels that reflect nutritionally relevant concentrations. A model
of the postmenopausal condition (ovariectomized rats) failed to show any notable uterine
differences between control and “low dose” genistein-treated animals during chronic
exposures (Rimoldi et al., 2007). The lack of an estrogenic effect for genistein in healthy
postmenopausal women was established in an NCI-sponsored Phase I trial (Bloedon et al.,
2002; Pop et al., 2008), which produced no significant estrogenic, toxic or genotoxic effects.
Taken together, these data indicate that genistein alone lacks pro-estrogenic effects on
proliferation under both pre- and postmenopausal conditions in rodents and humans, and
may antagonize estrogen-induced proliferation in the endometrium.
Estrogen is known to induce proliferation of endometrial cells in vivo, resulting in increased
uterine wet weight. Our previous studies using endometrial co-cultures have shown that
proliferation and differentiation of the reconstructed endometrial tissue in response to
variations of hormone levels is dependent on the presence of stromal cells (Arnold et al.,
2001; Arnold et al., 2002; Barbier et al., 2005; Barbier et al., 2008). In the current study we
confirmed a concentration-dependent increase in proliferation of endometrial epithelial cells
in co-cultures in response to increasing concentrations of estrogen that paralleled an increase
of estrogen-induced ER-dependent activation of ALPP gene activity, a well-characterized
marker of ER activation (Littlefield et al., 1990). Similar to estrogen, the phytoestrogen
genistein increased ER-mediated activation of ALPP activity over a range of physiologic
(nM) and super-physiologic (µM) concentrations. However a molar concentration of
genistein 500 times greater than that of estrogen was required to saturate this activation,
reflecting its notably higher affinity for ERβ compared to ERα. Unlike estrogen, genistein
alone had no effect on endometrial epithelial cell proliferation in co-cultures even at
concentrations shown to activate the ER-mediated ALPP activity. Previous research has
shown that both estrogen and genistein produce most of their cellular responses through
estrogen-responsive hormone receptor (ER) pathways but differences in the affinities of
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estrogen and genistein for the two ER subtypes (ERα versus ERβ) distinguish their potency
and their selective biological effects (Peterson, 1995). Therefore we used agonists that are
selective for ERα or ERβ in our co-culture system to determine whether the differences
observed in the effects of estrogen and genistein on endometrial cell proliferation resulted
from their relative binding efficiencies for ERα versus ERβ.
We found that both the ERα agonist PPT and the ERβ agonist DPN induced the ER-
mediated induction of ALPP activity. Like estrogen, PPT also increased cell proliferation in
our model system. Similar to the results produced by genistein alone, concentrations of the
ERβ agonist DPN that increased ALPP activity did not increase IK cell proliferation.
However a biphasic response of estrogen-stimulated IK cell proliferation was shown in co-
cultures to increasing concentrations of genistein. At nutritionally relevant concentrations (1
to 100 nM) genistein inhibited estrogen-induced IK cell proliferation through its preferential
activation of ERβ. While genistein selectively acts on the ERβ at nutritionally-relevant
concentrations, at a super-physiologic concentration (1 µM) it may also complement
estrogen to activate ERα. This concentration-dependent effect would result in the loss of the
anti-estrogenic effect of genistein on proliferation and induce proliferation above that caused
by estrogen alone (Figure 5B, column 6 versus column 2). Our findings suggest that at
physiologic concentrations (1 to 100 nM), genistein is preferentially activating ERβ and that
at a super-physiologic concentration (1000 nM) genistein loses its specificity for ERβ
resulting in a loss of its anti-estrogen effect. This premise is supported by our data showing
that lower concentrations of the ERβ-specific agonist DPN inhibit estrogen-induced
proliferation of IK cells in co-culture while higher concentrations decreased the inhibitory
effect (Figure 6). These results collectively support the hypothesis that physiologic genistein
predominantly affects the proliferation of IK cells in co-cultures in an ERβ-dependent
manner.
Reports in the literature indicate that ERβ activation in vivo yields an anti-proliferative
effect. ERβ knockout mice display increased uterine cell proliferation and are hyper-
responsive to estrogen when compared to the parental wild-type mice (Walker and Korach,
2004). Furthermore, these studies and those of Couse and Korach (Couse and Korach,
1999a; Couse et al., 1999b) emphasize the importance of the ERα subtype in the
proliferative responses of the endometrium to estrogen when ERβ is not operative. The
results presented in the current study indicate that concentrations of genistein that are found
in serum following typical Western dietary intake of soy products have a distinct anti-
estrogenic effect on endometrial cell proliferation when administered together with estrogen
in co-cultures. In contrast, these same concentrations of genistein increased ER-mediated
stimulation of ALPP activity similar to estrogen, but at much higher molar concentrations.
A point to note is that the concentration-dependent effects of genistein on epithelial cell
proliferation observed in the present study were found in co-cultures of endometrial
epithelial and stromal cells where genistein was present together with estrogen. Our previous
studies found that estrogen-induced proliferation of the epithelial cells normally is mediated
by paracrine factors secretion by stromal cells. While estrogen promoted an increase in cell
proliferation in IK cells in monocultures in the current studies, additions of high or low
concentrations of genistein along with estrogen had no discernable effect on IK cell
proliferation in monoculture. In contrast, co-cultures showed significant variations in
proliferation rates in response to estrogen with various concentrations of genistein. These
data indicate that the inhibitory effect of genistein in this co-culture model is mediated by
the stromal cells. Since genistein has a selective effect on ERβ our results suggest that
genistein is likely to be functioning via the ERβ in the stromal cells to counteract estrogen-
induced proliferation. At the highest concentration studied, genistein may have exceeded the
threshold for activation of ERα; the combination of negative (through ERβ) and positive
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(through ERα) regulation reduced inhibition of proliferation. Comparable results were found
with ERβ agonist DPN in co-cultures, though the restoration of estrogen-only proliferation
was not complete.
In summary, we found that concentrations of genistein associated with serum levels
achievable through dietary intake (i.e. 1 to 100 nM) are anti-proliferative in estrogen-
stimulated reconstructed endometrial tissue. Additionally, these effects were not observed in
IK cells cultured without stromal cells, indicating that the anti-proliferative response of
endometrial epithelial cells is determined by genistein effects on endometrial stromal cells.
These results with estrogen and genistein were shown to correlate with specific activation of
ERα or ERβ by chemical agonist PPT and DPN, respectively. The most compelling
evidence for the anti-estrogenic, and therefore potentially anti-cancer properties of genistein,
were demonstrated by the concentration-dependent inhibition of estrogen-induced IK cell
proliferation in the endometrial co-culture model system. These data indicate that
nutritionally relevant doses of genistein may have the potential for use as an anti-cancer
agent in pre- and peri-menopausal women at risk of estrogen-mediated malignant
transformation of the uterus. The results also suggest that micromolar concentrations of
genistein may potentiate estrogen-induced stimulation of endometrial proliferation
representing a novel risk factor for endometrial cancer. The dichotomous effects of genistein
on proliferation that we observed in IK cells in co-cultures, may then explain the
dichotomous relationship between genistein and endometrial cancer previously reported in
the literature.
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Figure 1. Estrogen and genistein induction of ER-regulated alkaline phosphatase activity in IK
cells in endometrial co-cultures
A. Estrogen activates the estrogen receptor in endometrial epithelial cells co-cultured with
endometrial stromal cells as determined by measuring alkaline phosphatase activity, a
known gene product of estrogen receptor activation. Column 1 = vehicle control, columns 2
through 7 are estrogen treatments at 0.01, 0.1, 1.0, 10, 100, 1000 nM. Results measured by
the ordinate are the ratio of the estrogen treated co-cultures to the untreated vehicle controls,
expressed as fold-increases. B. Genistein activates the estrogen receptor over a range of
physiologic concentrations; column 1 = vehicle control, columns 2 through 6 are genistein
treatments at 10, 50, 100, 500 and 1000 nM genistein. The height of the columns represents
the average of samples studied (N ≥ 8). **P < 0.01.
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Figure 2. Effects of estrogen and genistein on epithelial cell proliferation in endometrial co-
cultures
A. Estrogen increases endometrial epithelial cell proliferation in co-culture in a dose
dependent manner; column 1 = vehicle control, columns 2 – 6 = 0.1, 1.0, 10, 100 and 1000
nM estrogen. Results measured by the ordinate are the ratio of the estrogen treated co-
cultures to the untreated vehicle controls, expressed as fold-increases. B. Genistein fails to
induce endometrial epithelial proliferation in co-culture at concentrations shown to activate
the estrogen receptor (Figure 1B); column 1 = vehicle control, columns 2 – 4 = 1.0, 10 and
100 nM genistein. The height of the columns represents the average of samples studied (N ≥
4). **P < 0.01.
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Figure 3. Effects of estrogen receptor α- or β-specific agonists (PPT and DPN) on ER-regulated
alkaline phosphatase activity in endometrial co-cultures
A) The ERα-specific agonist PPT stimulates ER-regulated alkaline phosphatase activity over
a concentration range of 1.0 to 1000 nM (columns 3 to 6) when compared to vehicle control
(column 1), but does not achieve an activity equivalent to that of 10 nM estrogen (column
2). Results measured by the ordinate are the ratios of the estrogen or PPT-treated co-cultures
to the untreated vehicle controls, expressed as fold-increases. B) The ERβ-specific agonist
DPN stimulates ER-regulated alkaline phosphatase activity at concentrations ranging from
10 to 1000 nM (columns 4 to 6) when compared to vehicle control (column 1), but not at 1.0
nM (column 3). DPN also does not achieve an activity equivalent to that stimulated by 10
nM estrogen (10 nM, column 2) at the highest concentration tested (column 6). Results
measured by the ordinate are the ratios of the estrogen or PPT-treated co-cultures to the
untreated vehicle controls, expressed as fold-increases. The height of the columns represents
the average of the samples studied (N ≥ 11). **P < 0.01 versus vehicle control.
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Figure 4. Effects of estrogen receptor α- or β-specific agonists (PPT and DPN) on epithelial cell
proliferation in endometrial co-cultures
Estrogen (10 nM, column 2) and the ERα-agonist PPT (10 nM, column 3) both increased
endometrial epithelial cell proliferation in co-cultures significantly when compared to the
vehicle control (column 1). The ERβ-agonist DPN (10 nM, column 4) had no effect on
endometrial epithelial cell proliferation. Results measured by the ordinate are the ratios of
the estrogen or receptor-specific agonists to the untreated vehicle controls, expressed as
fold-increases. Data shown represents the average of the samples studied (N ≥ 3). **P <
0.01.
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Figure 5. Effects of estrogen and genistein co-treatment on epithelial cell proliferation in
monocultured versus co-cultured endometrial epithelial cells
A. In monocultures, estrogen induces a modest but significant increase in IK cell
proliferation (column 2 = 10 nM estrogen). Concurrent treatment with 10 or 1000 nM
genistein (column 3 = 10 nM estrogen + 10 nM genistein; column 4 = 10 nM estrogen +
1000 nM genistein) did not change IK cell proliferation. Results are presented as the ratios
of the estrogen or estrogen plus genistein to the untreated vehicle controls (column 1) shown
as fold-increases (ordinate). B. In co-cultures, genistein inhibits estrogen induced IK
proliferation (10 nM estrogen, column 2) in a biphasic manner. Physiologic concentrations
of genistein (1 to 100 nM) decreased estrogen-induced proliferation by 15%, 30% and 45%
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at 1.0 nM (column 3), 10 nM (column 4) and 100 nM (column 5), respectively. At a higher
concentration (1000 nM), genistein significantly increases the proliferative effects of 10 nM
estrogen (column 6) above that of estrogen alone (column 2). Results are presented as the
ratios of the estrogen or estrogen/genistein combinations to the untreated vehicle controls
(column 1) and are shown as fold-increases (ordinate). Data shown represent the average of
the samples studied (N ≥ 3). *P < 0.05 versus vehicle control, # P < 0.05 versus estrogen-
treated sample; **P < 0.01 versus vehicle control.
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Figure 6. Effect of the ERβ-agonist DPN on epithelial cell proliferation of IK cells in endometrial
co-culture
The estrogen receptor (ER)-β subtype specific agonist DPN inhibited estrogen-induced IK
proliferation in co-culture over a range of concentrations similar to that produced by
increasing concentrations of genistein. IK co-cultures were treated with 10 nM estrogen
(column 1) or increasing concentrations of DPN (0.1, 1.0, 10 and 100 nM; columns 2 – 5,
respectively). Inhibition of estrogen induced proliferation was maximal at a concentration of
10 nM DPN, above which DPN became less inhibitory. Results are presented as the ratios of
the estrogen/DPN combinations to the 10 nM estrogen-alone control (column 1) and are
shown as fold-increases (ordinate). **P < 0.01.
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